References
- Nicholson DW. Caspase structure, proteolytic substrates and function during apoptotic death. Cell Death Differ 1999; 6:1028 - 1042
- Stennicke HR, Salvesen GS. Properties of the caspases. Biochimica et Biophysica Acta 1998; 1387:17 - 31
- Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9:231 - 241
- Zhivotovsky B, Samali A, Gahm A, Orrenius S. Caspases: their intracellular localization and translocation during apoptosis. Cell Death Differ 1999; 6:644 - 651
- Samali A, Zhivotovsky B, Jones DP, Orrenius S. Detection of pro-caspase-3 in cytosol and mitochondria of various tissues. FEBS 1998; 431:167 - 169
- Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola-Rosen LA, et al. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol 1998; 140:1485 - 1495
- Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S. Presence of a pre-apoptotic complex of pro-caspse-3, Hsp60 and Hsp10 in the mitochondrial fraction of Jurkat cells. EMBO J 1999; 18:2040 - 2048
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323 - 331
- Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577 - 590
- Chipuk J, Kuwana T, Bouchier-Hayes L, Droin N, Newmeyer D, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010 - 1014
- Leu J, Dumont P, Hafey M, Murphy M, George D. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6:443 - 450
- Pietsch EEP, Canutescu A, Wang G, Dunbrack R, Murphy M. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem 2008; 283:21294 - 21304
- Cho Y, Gorina S, Jeffrey P, Pavletich N. Crystal structure of a p53 tumor suppressor-DNA complex: uncerstanding tumorigenic mutations. Science 1994; 265:346 - 355
- Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253:49 - 53
- Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006; 28:8600 - 8606
- Sayan BS, Sayan AE, Knight RA, Melino G, Cohen GM. p53 is cleaved by caspases generating fragments localizing to mitochondria. J Biol Chem 2006; 281:13566 - 13573
- Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993; 7:855 - 865
- Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25:47 - 54
- Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007; 9:573 - 580
- Pimkina J, Humbey O, Zilfou JT, Jarnik M, Murphy ME. ARF induces autophagy by virtue of interaction with Bcl-xl. J Biol Chem 2009; 284:2803 - 2810